In this article, we will explore the fascinating world of Indoramin, addressing its meanings, origins, impact on today's society and its relevance in different areas. Indoramin has been the subject of study and debate for decades, and its presence has become increasingly significant in our daily lives. From its impact on popular culture to its influence on technology, Indoramin has left its mark on history and continues to play a crucial role in the way we perceive the world around us. Throughout this article, we will analyze in detail the multiple aspects related to Indoramin, with the aim of providing a comprehensive and enriching vision of this very relevant topic.
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.043.659 |
| Chemical and physical data | |
| Formula | C22H25N3O |
| Molar mass | 347.462 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Indoramin (trade names Baratol and Doralese) is a piperidine antiadrenergic agent.
It is an alpha-1 selective adrenoceptor antagonist[1] with direct myocardial depression action; therefore, it results in no reflex tachycardia. It is also used in benign prostatic hyperplasia (BPH).[2]
It is commonly synthesized from tryptophol.[3]
Indoramin is commonly prescribed as 20 mg tablets when used in BPH.[4]
Drowsiness, dizziness, dry mouth, nasal congestion, headache, fatigue, weight gain, hypotension, postural hypotension, depression, problems with ejaculation, diarrhoea, nausea, increased need to pass urine, and palpitations.[5]
Tryptamine and serotonin are naturally occurring indole ethylamino compounds with pronounced pharmacological activities. They have served as the inspiration for synthesis of numerous analogues.
One such study involved alkylation of 4-benzamidopyridine (2) with a bromoethyy compound (1) derived from tryptophol, to give a quaternary pyridinium salt (3); this intermediate was in turn hydrogenated with a Raney nickel catalyst to give indoramine.[6][7]
On May 31, 2013, the French National Agency for the Safety of Medicines and Health Products (ANSM) concluded that the benefit/risk ratio of this product was unfavorable and withdrew Vidora's marketing authorization and recalled its batches from the market on June 3, 2013.[8]